Cargando…
Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial
This study investigated the gut microbiota and short chain fatty acids (SCFAs) characteristics of subjects with obesity from Xinjiang in northwestern China, a region with a multiethnic culture and characteristic lifestyle, and to explore the potential microbes that respond to a 12-wk medication of o...
Autores principales: | Jin, Jin, Cheng, Ruyue, Ren, Yan, Shen, Xi, Wang, Jiani, Xue, Yigui, Zhang, Huimin, Jia, Xiuhua, Li, Tingting, He, Fang, Tian, Haoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426637/ https://www.ncbi.nlm.nih.gov/pubmed/34512358 http://dx.doi.org/10.3389/fphar.2021.732541 |
Ejemplares similares
-
Orlistat and ezetimibe could differently alleviate the high-fat diet-induced obesity phenotype by modulating the gut microbiota
por: Jin, Jin, et al.
Publicado: (2022) -
Orlistat-Induced Gut Microbiota Modification in Obese Mice
por: Ke, Jing, et al.
Publicado: (2020) -
Ezetimibe and Cancer: Is There a Connection?
por: Gu, Jia, et al.
Publicado: (2022) -
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
por: Chilbert, Maya R, et al.
Publicado: (2022) -
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2009)